Innate Pharma announces today that it has started patient inclusion in a new multicenter Phase II clinical trial with IPH2101, an anti-KIR monoclonal antibody potentiating the anti-tumor activity of NK cells. In this trial, IPH 2101 is tested as a single agent in patients with smoldering myeloma, an early state of the blood malignancy multiple myeloma. The trial is conducted in the United States at multiple major hospitals (IPH2101-203 or “KIRMONO” trial).
| PR in English | 38.85 KB |
| CP en français | 39.61 KB |